Helixmith
Corporate brand
UnclaimedA South Korean biotechnology company developing gene therapies, cell therapies, antibodies, and botanical medicines.
Last updated October 17, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Helixmith is a South Korean biotechnology company headquartered in Seoul, with a United States presence in San Diego. Its principal business is the research and development of gene therapies, especially treatments intended to address diabetic peripheral neuropathy, diabetic foot ulcers, ischemic and neuromuscular diseases, and other conditions involving nerve damage or inadequate blood flow. The company was established in 1996 as the first on-campus startup associated with Seoul National University and initially operated under the name ViroMed. It changed its name to Helixmith in April 2019 and relocated its headquarters from its earlier Seoul National University research site to the Magok district of Seoul. The company has been publicly traded on the Korean Securities Dealers Automated Quotations market since 2006. Helixmith’s central technology platform is a non-viral plasmid DNA approach to gene delivery. Its lead candidate, Engensis, also known as VM202, is designed to deliver DNA encoding two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. The intended biological effects include stimulation of nerve regeneration, support for Schwann-cell and nerve-cell function, and promotion of microvascular formation. This approach is intended to provide a more sustained local production of HGF than direct administration of recombinant HGF protein, whose short biological half-life limits its persistence in the body. Engensis has been investigated in a range of clinical indications, including diabetic peripheral neuropathy, diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, intermittent claudication, and Charcot-Marie-Tooth disease. The company has described the program as having received several regulatory designations in the United States. VM202-ALS received orphan-drug and fast-track designations in 2016, while VM202-DPN received Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration in 2018. These designations reflected the potential medical need in the targeted conditions, but they did not constitute marketing approval or establish clinical efficacy. The lead program has also faced important development setbacks. In 2024, Helixmith reported that its phase III VM202-DPN study did not demonstrate superiority over placebo for diabetic peripheral neuropathy. This result materially affected the development outlook for the program, although the company’s broader pipeline and other indications remained part of its research portfolio. Beyond plasmid DNA gene therapy, Helixmith has pursued preclinical CAR-T cell programs through its subsidiary Cartexell, with an emphasis on solid tumors, and adeno-associated virus programs directed at neuromuscular diseases. It has also developed VM507, a fully human antibody intended to bind to and activate c-MET, the receptor for HGF. Preclinical work described by the company investigated possible applications in chronic kidney disease and renal fibrosis. The company’s activities extend beyond advanced therapeutics. Helixmith has worked on phytotherapeutics, natural medicines, health functional foods, and cosmetics based on plant-derived materials. Its botanical drug PG201 was approved in South Korea in 2012 for osteoarthritis and is marketed domestically as LAYLA tablets by a licensing partner. Another botanical candidate, HX204, has been described as a preclinical program for inflammatory bowel disease. Overall, Helixmith combines a gene-therapy-centered research identity with smaller or complementary programs in cell therapy, antibody therapeutics, and botanical medicine.
History
Helixmith traces its origins to 1996, when it was established as the first on-campus startup associated with Seoul National University. The company initially developed as a research-led biotechnology venture and adopted the name ViroMed in 1999. Its early identity was tied to the translation of university-linked biotechnology research into therapeutic development, eventually producing a pipeline centered on gene delivery and regenerative medicine. The company became publicly traded on South Korea’s KOSDAQ market in 2006. Over time, its research portfolio expanded beyond a single therapeutic concept. The principal platform became a non-viral plasmid DNA technology intended to deliver therapeutic genes without using a viral vector. This platform supported development of VM202, later branded Engensis, a plasmid construct encoding two HGF isoforms. The program was designed to promote angiogenesis and nerve regeneration and became the company’s most prominent clinical asset. Engensis entered clinical development across multiple disease areas. These included diabetic peripheral neuropathy and diabetic foot ulcers, as well as amyotrophic lateral sclerosis, coronary artery disease, intermittent claudication, and Charcot-Marie-Tooth disease. The range of indications reflected the company’s view that HGF-mediated vascular and neuroregenerative effects might be relevant to both ischemic and nerve-related disorders. U.S. regulatory agencies granted special designations to some of these programs: VM202-ALS received orphan-drug and fast-track designations in 2016, and VM202-DPN received Regenerative Medicine Advanced Therapy designation in 2018. Such designations were intended to facilitate development and regulatory interaction, but did not replace the need for positive controlled clinical-trial results and marketing authorization. In April 2019, ViroMed changed its corporate name to Helixmith. Around the same period, the company transferred its headquarters from its previous research facility at Seoul National University to Magok in Seoul. The new identity accompanied a broader presentation of the company as a biotechnology platform business rather than solely as a developer of one plasmid product. Helixmith subsequently maintained a diversified research portfolio. Its cell-therapy activities included preclinical CAR-T research conducted through Cartexell, with programs aimed at several types of solid tumors. It also pursued AAV-based gene-therapy candidates for neuromuscular diseases, including early programs associated with amyotrophic lateral sclerosis and multiple sclerosis. In antibody research, VM507 was developed as a fully human antibody capable of binding and activating c-MET, the receptor for HGF. Preclinical studies examined whether this mechanism could improve renal function or reduce fibrosis in models of kidney disease. The company also retained a botanical-medicine business. PG201, a plant-derived prescription treatment for osteoarthritis, received approval from South Korea’s Ministry of Food and Drug Safety in 2012 and was commercialized domestically under the LAYLA brand through a licensing arrangement. Helixmith described PG201 as having anti-inflammatory and cartilage-protective effects distinct from conventional nonsteroidal anti-inflammatory drugs. HX204 was another botanical candidate, positioned for inflammatory bowel disease and described as being at the preclinical stage. A major development setback occurred in 2024, when Helixmith disclosed that its phase III VM202-DPN trial failed to show superiority over placebo in diabetic peripheral neuropathy. The result weakened the near-term case for Engensis in that indication and became an important qualification to earlier expectations surrounding the lead program. Nevertheless, Helixmith continued to be characterized by a broader pipeline spanning plasmid DNA, AAV, CAR-T, antibody, and botanical approaches. Its history therefore reflects both the ambitions and risks of a clinical-stage biotechnology company whose principal asset has required prolonged testing across several difficult therapeutic areas.
- 2024
Phase III VM202-DPN trial does not meet superiority objective
[1]Helixmith reported that Engensis did not demonstrate superiority over placebo in a phase III study for diabetic peripheral neuropathy.
- 2019
ViroMed becomes Helixmith
[1]The company changed its corporate name to Helixmith and moved its Seoul headquarters to Magok.
- 2018
U.S. RMAT designation for VM202-DPN
[1]The U.S. FDA granted Regenerative Medicine Advanced Therapy designation to Engensis for diabetic peripheral neuropathy.
- 2016
U.S. orphan-drug and fast-track designations for VM202-ALS
[1]The Engensis program for amyotrophic lateral sclerosis received orphan-drug and fast-track designations in the United States.
- 2012
PG201 approved as a Korean botanical prescription drug
[1]PG201 received approval from South Korea’s Ministry of Food and Drug Safety for osteoarthritis and was later marketed as LAYLA tablets.
- 2006
KOSDAQ listing
[1]ViroMed became listed on South Korea’s KOSDAQ market under ticker 084990.
- 1999
Company adopts the ViroMed name
[1]The company changed its name to ViroMed as it developed its biotechnology and therapeutic research activities.
- 1996
Company established as a Seoul National University on-campus startup
[1]The biotechnology venture was founded as the first on-campus startup associated with Seoul National University.
Products and positioning
A South Korean biotechnology developer focused on gene therapies for neuropathic, ischemic, and neuromuscular diseases, supported by cell-therapy, antibody, and botanical-medicine programs.
Non-viral plasmid DNA gene therapy
Engensis (VM202)
Engensis is Helixmith’s lead gene-therapy candidate. It is a non-viral plasmid DNA construct designed to express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. The intended effects are to stimulate nerve regeneration and promote the formation of small blood vessels, potentially addressing both neuropathic symptoms and impaired circulation. The program has been studied in diabetic peripheral neuropathy, diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, intermittent claudication, and Charcot-Marie-Tooth disease. Its development has included U.S. regulatory designations, but the phase III diabetic peripheral neuropathy program reported no superiority over placebo in 2024.
Fully human antibody
VM507
VM507 is a fully human antibody intended to bind to and activate c-MET, the receptor for hepatocyte growth factor. Helixmith has investigated the candidate in preclinical models of kidney disease, where c-MET signaling was associated with reduced renal fibrosis and improved functional measures. The program was described as preclinical rather than an approved or commercially available medicine.
Botanical prescription medicine · 2012
PG201 / LAYLA tablets
PG201 is a plant-derived prescription treatment for osteoarthritis. It received approval from South Korea’s Ministry of Food and Drug Safety in 2012 and is marketed domestically under the LAYLA brand through a licensing arrangement. Helixmith has described the medicine as having anti-inflammatory and cartilage-protective activity, including effects on enzymes involved in cartilage degradation.
Botanical therapeutic
HX204
HX204 is a plant-derived therapeutic candidate being developed for inflammatory bowel disease. The program has been described as preclinical and as part of Helixmith’s broader phytotherapeutics pipeline.
Cell therapy
CAR-T programs
Helixmith has pursued CAR-T cell therapy through its subsidiary Cartexell. The research program is directed toward several solid-tumor types, an area in which cellular therapies face significant biological and manufacturing challenges. The programs described in the available reference material were at the preclinical stage.
AAV-vector gene therapy
AAV gene-therapy programs
The company has also maintained early-stage AAV-vector programs targeting neuromuscular diseases. The available material identifies research relevant to conditions including amyotrophic lateral sclerosis and multiple sclerosis, but does not provide named commercial products or approved therapies from this platform.
Controversies
2019
Goldman Sachs faces backlash over Helixmith outlook change
In October 2019, Goldman Sachs faced backlash from Helixmith and individual investors after changing its outlook on the Korean biopharmaceutical firm and sharply lowering its target price. Some investors suspected that the change was intended to facilitate short selling. The report presents this as a suspicion rather than an established finding, and no further details on the outcome or the parties involved are provided.
Brand decisions
2024
Disclosure of the VM202-DPN phase III resultOtherBackground
Engensis was being developed as a gene therapy for diabetic peripheral neuropathy, one of Helixmith’s principal clinical targets.
Action taken
Helixmith disclosed that the phase III trial did not demonstrate superiority over placebo.
Aftermath
The result reduced the evidentiary support for Engensis in diabetic peripheral neuropathy and became a significant development setback for the lead program.
2019
Corporate rebranding and headquarters relocationStrategyBackground
The company had operated under the ViroMed name since 1999 and was broadening its biotechnology identity around gene therapy and related therapeutic platforms.
Action taken
It changed its name to Helixmith and moved its headquarters from its former Seoul National University research facility to Magok, Seoul.
Aftermath
The reorganization established the Helixmith identity used for its subsequent gene-therapy, cell-therapy, antibody, and botanical-medicine activities.
Recent events
Reported
Goldman Sachs faces backlash over Helixmith outlook change[2]
Goldman Sachs faced backlash from Helixmith and individual investors after changing its outlook on the Korean biopharmaceutical firm and sharply lowering its target price. Some investors suspected the change was aimed at facilitating short selling; the article presents this as suspicion, not an established finding.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/helixmith · Editorial policy · How profiles are compiled